Enanta Pharmaceuticals | ENTA - Ingresos Por Ventas

Precio De Mercado
12.69
Cambio Diario
0.18 1.44%
Mensual
-13.97%
Anual
104.68%
Q1 Expectativa
12.13




Ventas Cambio Fecha
AbbVie USD 16.62B 840M 2025-12
Amgen USD 9.9B 340M 2025-12
Anika Therapeutics USD 30.62M 2.8M 2025-12
Arrowhead Research USD 264.03M 7.56M 2025-12
AstraZeneca USD 15.5B 313M 2025-12
BioCryst Pharmaceuticals USD 406.56M 247.16M 2025-12
Biogen USD 2.28B 250M 2025-12
Bristol-Myers Squibb USD 12.5B 300M 2025-12
Enanta Pharmaceuticals USD 16.96M 50.68M 2024-12
Gilead Sciences USD 7.93B 130M 2025-12
GlaxoSmithKline GBP 8.62B 73M 2025-12
Halozyme Therapeutics USD 451.76M 97.76M 2025-12
Heron Therapeutics USD 40.59M 2.38M 2025-12
Incyte USD 1.51B 140M 2025-12
Insmed USD 263.8M 121.8M 2025-12
Ionis Pharmaceuticals USD 203M 46M 2025-12
J&J USD 24.6B 610M 2025-12
Karyopharm Therapeutics USD 30.54M 8.24M 2024-12
Ligand Pharmaceuticals USD 59.66M 55.8M 2025-12
Merck USD 16.4B 880M 2025-12
Neurocrine Biosciences USD 805.5M 10.6M 2025-12
Novartis USD 13.86B 50M 2025-12
Novavax USD 147.14M 76.69M 2025-12
Pfizer USD 17.58B 880M 2025-12
PTC Therapeutics USD 164.7M 46.3M 2025-12
Roche Holding CHF 15.65B 274.5M 2025-12
Sarepta Therapeutics USD 442.9M 43.5M 2025-12
Vertex Pharmaceuticals USD 3.19B 110M 2025-12